VIDEO: ‘We should be exploring’ sodium-glucose inhibitors in cirrhosis treatment

ByPaul Kwo, MD

ByMarley V. Ghizzone

Fact checked byHeather Biele

PHILADELPHIA — In this video, Paul Kwo, MD, professor of medicine and director of hepatology at Stanford University, highlights a presentation evaluating the use of sodium-glucose cotransporter 2 inhibitors in patients with cirrhosis.

The data were presented at the ACG Annual Scientific Meeting.

“Indeed, there is a small amount of data that show you can actually use SGLT2 inhibitors for individuals with refractory ascites or refractory hepatic hydrothorax,” Kwo said. “And, indeed, this lends more credence to the notion that we should be exploring SGLT2 inhibitors in patients with cirrhosis to prevent decompensation events.”

Reference:

Abu-Hammour MN, et al. Association of sodium glucose co-transporter-2 inhibitors and serious liver events in patients with cirrhosis on diuretics: A global cohort study. Presented at: ACG Annual Scientific Meeting; Oct. 25-30, 2024; Philadelphia (hybrid meeting).

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Kwo reports serving as an advisor or review panel member for AbbVie; an advisory committee or board member for Aligos, Drug Farm, Gilead and Inventiva; receiving grant or research support from Altimmune, Fractyl, Gilead, Inventiva, Madrigal, Novo Nordisk, Target Registries and Ultragenyx; serving as a consultant for Durect, HepQuant, PPD and Surrozen; and owning stock options in Durect.

Discoveries in Liver

Read more

VIDEO: ‘We should be exploring’ sodium-glucose inhibitors in cirrhosis treatment

Reference:

Related Content